The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Fresenius has entered into a global licensing agreement for the commercialisation of Polpharma vedolizumab biosimilar candidate PB016.

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide.

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

England has launched a world-first gonorrhoea vaccination programme that will potentially help avert up to 100,000 cases of the disease and save millions of NHS funding.